Publication at Faculty of Physical Education and Sport, First Faculty of Medicine |
2018
Abstract
Research over the past decade has allowed the modulation of immune processes to reactivate anti-tumor immune mechanisms. Antibodies against the PD-1 receptor and its PD-L1 ligand are the main focus of recent studies.
Atezolizumab is a humanized IgG1-type monoclonal antibody that binds to PD-L1. It is currently registered for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy and for locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy or in patients who are unable to undergo cisplatin therapy.